CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc. is a biotechnology company developing engineered cell therapies for the treatment of cancer. The company’s approach is designed to combine the tumor-targeting capabilities of T cells with the engulfing and clearing functions associated with macrophages, potentially enabling immune cells to attack cancer through multiple mechanisms.

CERo’s therapeutic platform uses genetically modified T cells intended to recognize tumor-associated targets and directly destroy or phagocytose malignant cells. Its lead investigational program, CER-1236, is designed to target CD70, a protein expressed in certain blood cancers and solid tumors. The program has been developed as a potential treatment for patients with cancers that may be difficult to address with conventional T-cell therapies.

The company was formed to advance its engineered cell-therapy platform and became a publicly traded company through a business combination completed in 2024. CERo Therapeutics is based in the United States and focuses its research and development activities on oncology applications. Its products remain investigational and are subject to clinical and regulatory development.

Key Stats

• Today's Range: $0.0035 to $0.0050
• 50-Day Range: $0.0034 to $0.0158
• 52-Week Range: $0.00 to $0.14
• Volume: 90,167 shs
• Average Volume: 644,996 shs
• Market Capitalization: $358.16 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

CERo Therapeutics Stock Analysis - MarketRank™

CERo Therapeutics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

CERo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

CERo Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CERo Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CERO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CERo Therapeutics does not currently pay a dividend.

Dividend Growth

CERo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CERo Therapeutics this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for CERO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CERo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.36% of the stock of CERo Therapeutics is held by insiders.

Percentage Held by Institutions

29.64% of the stock of CERo Therapeutics is held by institutions.

Company Calendar

• Today: 11/10/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CIK: 1870404
• Web: www.cero.bio
• Phone: (650) 407-2376
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($9.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -209.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($41.98) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 71,631,000
• Free Float: 1,052,000
• Market Cap: $358.16 thousand
• Optionable: N/A
• Beta: 0.27